Modified RNA Technology for Targeting

At WiNK, we are pioneering treatment approaches for diabetes and solid tumors through our innovative modified RNA aptamer therapeutics. Our initial focus is on Type 1 diabetes, supported by compelling proof-of-concept data showing that our bifunctional RNA therapeutics precisely target human pancreatic beta islet cells. Our flagship assets, WT817 and WT931, uniquely enable beta cell regeneration and protection—an unprecedented breakthrough in the pharmaceutical industry for a non-cell-based treatment modality.

Diabetic Complications

There currently is no cure for Type 1 Diabetes. The standard of care for patients with Type 1 Diabetes is to manage the disease through lifelong insulin replacement therapy, typically administered via multiple daily injections or an insulin pump, combined with careful monitoring of blood sugar levels through diet, exercise, and regular glucose testing. Type 1 diabetes can lead to many long term health complications.

Average lifespan shortened by approximately 12 years, similar to the average decrease caused by all cancers.

Source: Mortality in Type 1 Diabetes in the Current Era Michelle Katz, MD, MPH1,2,3; Lori Laffel, MD, MPH1,3 JAMA Jan 2015

Curing Type 1 Diabetes (T1D)

Traditional Approach

Historically, approaches to attempt to cure Type 1 Diabetes involved surgically implanting an external islet cell product.

Success rates low and variable due to limitations including:

  • Lack of donor availability
  • Risk associated with required lifelong immunosuppressive medications
  • Transplanted islets gradually losing function over time
  • Only a small subset of patients, those with severe and poorly controlled type 1 diabetes qualifying as candidates

Curing Type 1 Diabetes (T1D)

WiNK Approach

We use injectable RNA therapeutics to restore a person’s own glucose control system, by restoring pancreatic beta cell mass and protecting these cells from T-cell attack.